Mankind Pharma Acquires Bharat Serums and Vaccines for Rs 13,630 Crore

Mankind Pharma announced the full acquisition of Bharat Serums and Vaccines from Advent International for approximately Rs 13,630 crore. This move positions Mankind Pharma as a leader in the Indian women's health and fertility drug market while giving it access to other critical care products with advanced R&D technologies.

Mankind Pharma on Thursday announced its complete acquisition of Bharat Serums and Vaccines from Advent International for an estimated Rs 13,630 crore.

This strategic move is part of a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines, positioning Mankind Pharma as a prominent player in the Indian women's health and fertility drug market.

Additionally, the acquisition grants Mankind Pharma access to high entry barrier products in critical care, backed by established complex R&D tech platforms, cementing its leadership in the pharmaceutical industry.

(With inputs from agencies.)